Active lymphotoxin-β receptor immunoglobulin chimeric protein compositions
View Patent ↗Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification.
1. A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 10% of the LT-β-R-Ig fusion proteins are inactive.
2. The composition of claim 1 , wherein the active LT-β-R-Ig fusion proteins are recognized by a functional specific antibody.
3. The composition of claim 1 , wherein the LT-β-R-Ig fusion protein comprises a human Fc domain.
4. A pharmaceutical composition comprising the composition of claim 3 , and a pharmaceutically acceptable carrier.
5. The composition of claim 1 , wherein the Fc domain is of an IgG1 isotype.
6. A pharmaceutical composition comprising the composition of claim 5 , and a pharmaceutically acceptable carrier.
7. A composition comprising active and inactive lymphotoxin- β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins, wherein no more than 10% LT-β-R-Ig fusion proteins are inactive, and wherein the active LT-β-R-Ig fusion proteins are obtained by culturing a mammalian host cell transformed with DNA encoding the LT-β-R-Ig fusion protein in a culture system having a temperature of about 27° C. to less than about 30° C.
8. The composition of claim 7 , wherein the LT-β-R-Ig fusion protein comprises a human Fc domain.
9. A pharmaceutical composition comprising the composition of claim 8 , and a pharmaceutically acceptable carrier.
10. The composition of claim 8 , wherein the Fc domain is of an IgG1 isotype.
11. A pharmaceutical composition comprising the composition of claim 10 , and a pharmaceutically acceptable carrier.
12. The composition of claim 1 , wherein the active LT-β-R-Ig fusion proteins are glycosylated.
13. A composition comprising active lymphotoxin -β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 6% of the LT-β-R-Ig fusion proteins are inactive.
14. The composition of claim 13 , wherein the LT-β-R-Ig fusion protein comprises a human Fc domain.
15. The composition of claim 13 , wherein the active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins are glycosylated.
16. A pharmaceutical composition comprising the composition of claim 13 , and a pharmaceutically acceptable carrier.
17. The composition of claim 14 , wherein the Fc domain is of an IgG1 isotype.
18. A pharmaceutical composition comprising the composition of claim 17 , and a pharmaceutically acceptable carrier.